Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

阿西替尼 医学 舒尼替尼 彭布罗利珠单抗 肾细胞癌 肿瘤科 内科学 泌尿科 癌症 免疫疗法
作者
Brian I. Rini,Elizabeth R. Plimack,Viktor P. Stus,Rustem Airatovich Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,B. Yа. Alekseev,Denis Soulières,Bohuslav Melichar,Ihor O. Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sérgio Jobim Azevedo,Delphine Borchiellini,Cezary A. Szczylik,Maurice Markus,Ray McDermott,Jens Bedke,Sophie Tartas
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:380 (12): 1116-1127 被引量:3708
标识
DOI:10.1056/nejmoa1816714
摘要

BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CYQ完成签到,获得积分10
刚刚
xiaoyu完成签到,获得积分10
刚刚
共享精神的应助被酷酷柚子采纳,获得10
刚刚
情怀的应助被酷酷柚子采纳,获得10
刚刚
无花果的应助被炸鱼饼大人采纳,获得10
刚刚
Doctor_Lee30完成签到,获得积分10
刚刚
珍珠发布了新的文献求助10
刚刚
刚刚
米花完成签到 ,获得积分10
1秒前
chen发布了新的文献求助10
1秒前
芝士糊了吧完成签到,获得积分10
1秒前
zhuoz完成签到,获得积分10
1秒前
源源完成签到,获得积分10
2秒前
2秒前
2秒前
lucky完成签到,获得积分10
3秒前
min发布了新的文献求助10
3秒前
xiaolv发布了新的文献求助10
3秒前
little_cheetah完成签到,获得积分10
3秒前
请较老嘚发布了新的文献求助10
3秒前
影子芳香完成签到 ,获得积分10
3秒前
美丽万声完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
5秒前
5秒前
K13完成签到,获得积分10
5秒前
zilicai的应助被VDC采纳,获得10
5秒前
科研通AI6.3的应助被LGX采纳,获得10
5秒前
大个的应助被科研怪采纳,获得10
6秒前
ting33625完成签到,获得积分20
6秒前
香蕉觅云的应助被chen采纳,获得10
6秒前
小二郎的应助被袁志阳采纳,获得10
7秒前
7秒前
soob完成签到 ,获得积分10
7秒前
冷酷以山发布了新的文献求助10
8秒前
彭于晏的应助被愉快的友绿采纳,获得10
8秒前
ding的应助被宿敌采纳,获得10
8秒前
小任同学完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460